Literature DB >> 11708496

Quantitative analysis of Epstein-Barr virus DNA in plasma and serum: applications to tumor detection and monitoring.

Y M Lo1.   

Abstract

The recent interest in cell-free tumor-derived DNA in the plasma and serum of cancer patients has opened up numerous diagnostic possibilities. One type of tumor-derived DNA that has been detected in plasma/serum is viral DNA. One example of circulating viral nucleic acid is Epstein-Barr virus (EBV) DNA, which has been found in the plasma and serum of patients with nasopharyngeal carcinoma (NPC), certain lymphomas, and gastric carcinoma. Quantitative analysis of circulating EBV DNA in NPC has demonstrated a positive correlation with disease stage and a strong relationship with clinical events, as well as being of prognostic importance. For EBV-associated lymphomas, quantitative EBV DNA analysis has also been found to correlate closely with clinical progress. It is expected that plasma/serum EBV DNA analysis will soon be incorporated into the routine investigative protocol of EBV-associated malignancies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11708496     DOI: 10.1111/j.1749-6632.2001.tb03865.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  19 in total

1.  The mTOR inhibitor manassantin B reveals a crucial role of mTORC2 signaling in Epstein-Barr virus reactivation.

Authors:  Qian Wang; Nannan Zhu; Jiayuan Hu; Yan Wang; Jun Xu; Qiong Gu; Paul M Lieberman; Yan Yuan
Journal:  J Biol Chem       Date:  2020-04-20       Impact factor: 5.157

2.  (-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves downregulation of latent membrane protein 1.

Authors:  Sufang Liu; Hongde Li; Min Tang; Ya Cao
Journal:  Exp Ther Med       Date:  2017-11-13       Impact factor: 2.447

3.  Current management strategy of nasopharyngeal carcinoma.

Authors:  William I Wei; Dora L W Kwong
Journal:  Clin Exp Otorhinolaryngol       Date:  2010-03-30       Impact factor: 3.372

4.  Virologic Diagnosis, Viral Monitoring, and Treatment of Epstein-Barr Virus Infectious Mononucleosis.

Authors:  Hal B. Jenson
Journal:  Curr Infect Dis Rep       Date:  2004-06       Impact factor: 3.725

5.  Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.

Authors:  J S Kalpoe; P B Douwes Dekker; J H J M van Krieken; R J Baatenburg de Jong; A C M Kroes
Journal:  J Clin Pathol       Date:  2006-02-17       Impact factor: 3.411

6.  Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance.

Authors:  Y-L Kwong; A W K Pang; A Y H Leung; C-S Chim; E Tse
Journal:  Leukemia       Date:  2013-07-11       Impact factor: 11.528

Review 7.  The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases.

Authors:  Wenna Zhang; Yupei Chen; Lei Chen; Rui Guo; Guanqun Zhou; Linglong Tang; Yanping Mao; Wenfei Li; Xu Liu; Xiaojing Du; Ying Sun; Jun Ma
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

Review 8.  Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis.

Authors:  Hongde Li; Sufang Liu; Jianmin Hu; Xiangjian Luo; Namei Li; Ann M Bode; Ya Cao
Journal:  Int J Biol Sci       Date:  2016-10-18       Impact factor: 6.580

Review 9.  Antiviral Effects of Green Tea EGCG and Its Potential Application against COVID-19.

Authors:  Ying-Qi Wang; Qing-Sheng Li; Xin-Qiang Zheng; Jian-Liang Lu; Yue-Rong Liang
Journal:  Molecules       Date:  2021-06-29       Impact factor: 4.411

Review 10.  Building the Evidence Base of Blood-Based Biomarkers for Early Detection of Cancer: A Rapid Systematic Mapping Review.

Authors:  Lesley Uttley; Becky L Whiteman; Helen Buckley Woods; Susan Harnan; Sian Taylor Philips; Ian A Cree
Journal:  EBioMedicine       Date:  2016-07-06       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.